We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.34 | -2.96132596685 | 45.25 | 47.1 | 43.625 | 780394 | 45.05779158 | CS |
4 | 3.35 | 8.25936883629 | 40.56 | 49.4999 | 39.27 | 771011 | 44.84525675 | CS |
12 | -3.59 | -7.55789473684 | 47.5 | 52.035 | 39.27 | 643383 | 45.46790435 | CS |
26 | 19.77 | 81.8972659486 | 24.14 | 52.035 | 22.26 | 577703 | 39.11650566 | CS |
52 | 23.14 | 111.410688493 | 20.77 | 52.035 | 19.805 | 435195 | 33.62918451 | CS |
156 | 21.85 | 99.0480507706 | 22.06 | 52.035 | 12.03 | 363260 | 26.81526735 | CS |
260 | 29.21 | 198.707482993 | 14.7 | 52.035 | 10.18 | 257618 | 25.3212103 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions